Recro Pharma, Inc. (REPH): Winston J Churchill , director of Recro Pharma, Inc. sold 58,331 shares on Nov 23, 2015. The Insider selling transaction was reported by the company on May 23, 2016 to the Securities and Exchange Commission. The shares were sold at $8.27 per share for a total value of $461,392.44 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 23, 2016, Wayne Weisman (director) sold 58,331 shares at $8.27 per share price.On May 23, 2016, Abraham Ludomirski (director) sold 58,331 shares at $8.27 per share price.Also, On May 23, 2016, Vitalife Partners Ii Lp Scp (10% owner) sold 18,740 shares at $6.45 per share price.On May 23, 2016, Vitalife Partners (israel) Scp (10% owner) sold 6,260 shares at $6.45 per share price.
Shares of Recro Pharma Inc (REPH) ended Friday, May 20, 2016 session in red amid volatile trading. The shares closed down -0.22 points or -3.36% at $6.32 with 45,322 shares getting traded. Post opening the session at $6.5, the shares hit an intraday low of $6.3 and an intraday high of $6.65 and the price vacillated in this range throughout the day. The company has a market cap of $59,838 M and the number of outstanding shares has been calculated to be 9,46,80,00,000 shares. The 52-week high of Recro Pharma Inc is $18.3 and the 52-week low is $5.59.
Recro Pharma Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies) especially of the lower extremities which can occur in diabetic patients.